Development and validation of a risk prediction model for lost to follow-up among adults on active antiretroviral therapy in Ethiopia: a retrospective follow-up study

Dawit Tefera Fentie1*, Getahun Molla Kassa1, Sofonyas Abebaw Tiruneh2 and Achenef Asmamaw Muche1

Abstract

Background: Over 420,000 people have initiated life-saving antiretroviral therapy (ART) in Ethiopia; however, lost-to-follow-up (LTFU) rates continue to be high. A clinical decision tool is needed to identify patients at higher risk for LTFU to provide individualized risk prediction to intervention. Therefore, this study aimed to develop and validate a statistical risk prediction tool that predicts the probability of LTFU among adult clients on ART.

Methods: A retrospective follow-up study was conducted among 432 clients on ART in Gondar Town, northwest, Ethiopia. Prognostic determinants included in the analysis were determined by multivariable logistic regression. The area under the receiver operating characteristic (AUROC) and calibration plot were used to assess the model discriminative ability and predictive accuracy, respectively. Individual risk prediction for LTFU was determined using both regression formula and score chart rule. Youden index value was used to determine the cut-point for risk classification. The clinical utility of the model was evaluated using decision curve analysis (DCA).

Results: The incidence of LTFU was 11.19 (95% CI 8.95–13.99) per 100-persons years of observation. Potential prognostic determinants for LTFU were rural residence, not using prophylaxis (either cotrimoxazole or Isoniazid or both), patient on appointment spacing model (ASM), poor drug adherence level, normal Body mass index (BMI), and high viral load (viral copies > 1000 copies/ml). The AUROC was 85.9% (95% CI 82.0–89.6) for the prediction model and the risk score was 81.0% (95% CI 76.7–85.3) which was a good discrimination probability. The maximum sensitivity and specificity of the probability of LTFU using the prediction model were 72.07% and 83.49%, respectively. The calibration plot of the model was good (p-value = 0.350). The DCA indicated that the model provides a higher net benefit following patients based on the risk prediction tool.

Conclusion: The incidence of LTFU among clients on ART in Gondar town was high (> 3%). The risk prediction model presents an accurate and easily applicable prognostic prediction tool for clients on ART. A prospective follow-up study and external validation of the model is warranted before using the model.

Keywords: Lost to follow up, HIV/AIDS, Risk prediction, Risk score, Regression formula

Introduction

Human immunodeficiency virus (HIV) is a significant global public health issue claiming almost 33 million lives so far [1]. With increasing access to effective HIV programs, HIV infection has become one of manageable
chronic health condition, enabling people living with HIV to lead long and healthy lives [2]. However, ART programs in low and middle-income countries (LMIC) are characterized by high rates of loss to follow-up from care (LTFU), up to 40% after 5 years of ART [3]. Thus, LTFU is threatening optimal standard achievement in attaining near-universal ART coverage.

The United Nations acquired immunodeficiency syndrome (UNAIDS) fast-track goals, commonly referred to as the 95-95-95 goals, recommend countries should have 95% of HIV-infected persons know their HIV status, 95% of those who know their HIV positive status should initiate ART and 95% of those on treatment should have viral suppression (<1000 copies/ml) by 2030 to control the global HIV pandemic [4].

Good adherence to ART treatment is essential in achieving viral suppression and reduction in HIV transmission [5]. However, many countries in sub-Saharan Africa (SSA) still suffer from high rates of LTFU on ART, poor adherence to treatment, and low retention rates. A systematic and meta-analysis research which was done in LMIC with a total sample size of 1,605,320 clients of which 87.4% where from SSA has reported the percentage of patients identified as LTFU varied between 2.8 and 65.6% [6]. In Ethiopia, currently there are around 420,000 people on ART [7], while a systematic and meta-analysis study has revealed a large proportion (11.86% to 18.47%) of clients on ART were LTFU [8].

Knowledge of risk factors for LTFU can contribute to improve individualized patient care and inform policymakers on a programmatic level. Let alone the rest part of the world, in recent years, a substantial number of studies in Ethiopia have revealed a wide range of sociodemographic male sex [9–16], rural residence [17–20], older age [18, 21, 22], type of work-being daily laborer [18, 21, 23], educational status [15, 22–24], and unmarried [15, 23], clinical parameters (underweight BMI [9, 22, 25], type of regimen [9, 21, 24], lower CD4 cells [14, 23, 25–27], advanced WHO staging [12, 17, 26–28], poor drug adherence [18, 25, 27], not taking prophylaxis isoniazid [25, 27–29] and/or cotrimoxazole preventive therapy [20, 21, 30], presence of opportunistic infection [25, 26, 29], bed-reddened patients [12, 21, 25–27], having adverse drug reaction [28, 29], and mental illness [19, 20], personal and behavior-related (absence of care giver [19, 20], substance abusers [23, 31], not disclosing HIV status [11, 30] and fear of stigma [19, 24] and health system-related (less burden health facilities [14, 16, 22, 26] determinants that are independently associated with LTFU.

Despite the significant number of individual studies on incidence and predictors of LTFU, to this date and to our knowledge, there is no means or tool to identify patients at higher risk for LTFU among clients on ART. Previous studies concluded that risk factors for LTFU in HIV care are known, but individual prediction tools are lacking [32], and predicting lost to follow-up using routinely collected data was not successful [33]. Consequently, developing a prediction tool would help in differentiating such patients at higher risk of LTFU and thus, it would assist health professionals in providing special care for such patients and minimizing LTFU along with preventing the grave consequences following it. We believe that if clinics with limited resources could easily use an accurate tool for predicting LTFU, might help them modify services that would optimize health care delivery. Thus, our goal was to develop and validate a practical clinical prognostic risk prediction tool that will use routinely collected data from HIV clinics to predict LTFU among clients on ART.

**Methods and materials**

**Study design, area, and period**

An institutional-based retrospective follow-up study with a prognostic approach was conducted from October 2016 to April 2021 among adult clients on ART among health facilities in Gondar town. Gondar town is the main city of the central Gondar zone located 750 km away from Addis Ababa, the capital city of Ethiopia. The town has eight government health centers and one specialized referral hospital (University of Gondar compressive and specialized hospital) which provides acute and chronic HIV/AIDS care. The University of Gondar compressive and specialized hospital is a teaching hospital that serves more than seven million people of the central Gondar zone and people of the neighboring zones.

**Source and study populations**

The source population includes all adult (age 18 years and above) HIV-positive patients who have started ART and have a follow-up in Gondar town health facilities from October 2016 to April 2021 (starting the universal test and treat strategy) to April 2021. The study population was those clients on ART from the University of Gondar compressive and specialized hospital, Gondar health center, and Marakie health center from the start of the universal test and treat strategy in the town (October 2016 to April 2021). We have included all adult (age 18 years and above) HIV positive patients on ART in Gondar town from October 2016 to April 2021 and those patients with incomplete information for outcome variable (lost to follow up, dead, drop, transfer out) and ART initiation was excluded from this study.

**Sample size determination and sampling technique**

The sample size was determined by using the formula...
Time to LTFU: Time to LTFU was calculated in years according to the time interval between the dates of ART initiation to LTFU.

Rapid ART initiation: defined as starting ART within 7 days.

Late ART initiation: defined as starting ART after 7 days of HIV diagnosis.

Transfer Out (TO): Refers to the date on which a patient who has been receiving ART at one facility transfers out of that facility and receives the treatment at other facilities.

Dead (D): A patient who died at any time after being enrolled in HIV care.

Non-adherent: patients who are labeled as having “Poor” or “Fair” adherence in ART follow up card.

Adherent: patients who are labeled as having “Good” adherence in ART follow-up card.

High viral load (HVL): patients with a viral load above 1000 copies/ml after 6 months of initiation of ART.

Operational definitions

Lost to follow up (LTFU): A patient who has not been seen at the clinic for at least 30 to 90 days (3 months) after the last missed appointment, but has not transferred out or dead.

Defaulter: is a client who has not turned up for either a clinical visit or refill 7 days after their scheduled appointment date but is not a patient classified as LTFU.

Drop a client who has not turned up or come back to the clinic for either a clinical visit or refill for more than 90 days (3 months) from the last scheduled visit.
tables, mean with standard deviations (SD) for normally distributed continuous variables, percentages, and rates were employed. Incidence of lost follow was computed. First, binary logistic regression was fitted to see the association of each potential determinant with the incidence of LTFU among patients on ART. All variables with a p-value < 0.25 in the bi-variable analysis were included in the multivariable model. As well, least absolute shrinkage and selection operator (LASSO) regression was considered for variable selection for the multivariable model. The two-sided p-value less than 0.05 was considered statistically significant. So that the final multivariable binary logistic regression model (logit) was considered as the following model equation.

\[
\logit(y) = \beta_0 + \beta_1 x_1 + \cdots + \beta_k x_k
\]

where y is the binary dependent variable (Lost follow-up or not), \(\beta_0\) is the constant when all predictors are equated to zero, \(\beta_i\) is the ith coefficient for determinants \(i, i = 1, 2, 3, \ldots\), \(k_i\) is the ith determinant variable.

Assessment of the model performance and validation
Model calibration was assessed by plotting deciles of the predicted probability of lost follow-up against the observed rate of LTFU in each decile and fitting a smooth line. The AUROC curve was done to see the model discrimination probability using ‘pROC’ and the calibration plot was checked using ‘givitiR’ R-packages. The AUROC value of 0.5 indicates no predictive ability while 0.7 and above is considered as good and one is perfect prediction probability. The regression coefficients with their 95% confidence intervals and AUROC were internally validated using the binormal smoothing bootstrapping technique. The bootstrap method with 2000 iterations of re-samplings with replacements to create bootstrap datasets and bootstrapping was used to adjust for optimism/overfitting in the predictive ability of the model. After bootstrapping, the model’s predictive performance was considered the performance that can be expected when the model is applied to future similar populations. To evaluate the clinical and public health impact of the model, we performed a decision curve analysis (DCA) of standardized net benefit across a range of threshold probabilities (0 to 1). In the DCA, the model was compared against two extreme scenarios; “intervention for all” and “no intervention”. In our case, the intervention considered was using the model for the prediction of LTFU for all patients.

As well, for the ease of clinical preference the individualized risk prediction was classified also using a regression formula based on the Bernoulli distribution formula.

\[
\logit(\pi) = \alpha \beta x_1 + \cdots + \beta_n x_n.
\]

Results
Socio-demographic variables of the study participants
Out of 432 study subjects, 230 (53.24%) were females. The mean age was 33.83 years with a Standard deviation (SD) ± 10.04 years. Most participants were Orthodox Christian (382, 88.43%), and more than half were unmarried (261, 60.42%). The majority of patients were from Gondar town (urban) (353, 81.71%). More than two-thirds of patients (309, 71.53%) had formal education and more than half (228, 53.78%) were employed. Concerning disclosure, 236 (54.63%) patients did not disclose their HIV status (Table 1).

Baseline clinical characteristics of patients at ART initiation
One-third of patients knew their HIV status and has started ART in the same facility where they were diagnosed. Along with ART, nearly two-thirds of patients (281, 65.05%) were also on prophylaxis (CPT 11.11%, INH 37.96%, on both (CPT and INH), 15.97%) while more than one-third of patients (151, 34.95%) were not taking prophylaxis because they were not eligible as per the national guideline which was documented in their respective charts. The majority of patients (317, 73.38%) were adherent to their medication. Since the current strategy is “test and treat”, the majority of patients (366, 84.72%) were working and were not having advanced diseases (WHO stage III/IV) (368, 85.19%) while they were starting ART (Table 2).

Prognostic individualized prognostic risk prediction development
To construct an easily applicable score chart rule was used. The predicted probability of LTFU was presented according to two categories of the risk score for statistical stability and practical applicability using the Youden index value. The categories were chosen with a view to a reasonable size of each type and clinical sensibility, and the classification was high or low risk for LTFU. The risk score category was categorized using sensitivity, specificity, the positive and negative predictive value of the risk score model using different cut-point values. Finally, the probability of LTFU for each patient on ART was predicted using the linear predictor of estimated risk of lost follow up which is:

\[
P \text{ (Risk score for each patient)} = \text{risk score} \times \text{prognostic determinant} + \cdots + N \text{ (risk score)} \times N \text{ (prognostic determinant)}
\]
A predictive model for LTFU among clients on ART

For the prediction of LTFU, the patient’s socio-demographic, personal and behavioral, clinical, and system-related prognostic determinants were considered. In the bi-variable binary logistic model, among the considered determinants: HIV disclosure status, prophylaxis status, ASM status, functional status, date of initiation for ART, educational status, adherence status, age, partner HIV status, caregiver status, residence, BMI, WHO clinical staging, HVL status, and marital status were significant predictors of LTFU and were fitted to the multivariable binary logistic regression model. While in the multivariable binary logistic regression model: not on prophylaxis

Table 1 Baseline socio-demographic characteristics of adult clients on ART in Gondar town, Oct 2016 to April 2021 (n = 432)

| Characteristics       | Frequency (n) | Percentage (%) |
|-----------------------|---------------|----------------|
| Age (years)           |               |                |
| 18–50                 | 380           | 87.96          |
| > 50                  | 52            | 12.04          |
| Sex                   |               |                |
| Male                  | 202           | 46.76          |
| Female                | 230           | 53.24          |
| Marital status        |               |                |
| Never married         | 103           | 23.84          |
| Married               | 171           | 39.58          |
| Divorced              | 131           | 30.32          |
| Widowed               | 27            | 6.25           |
| Level of education    |               |                |
| No formal education   | 123           | 28.47          |
| Primary               | 123           | 28.47          |
| Secondary             | 130           | 30.09          |
| Tertiary              | 56            | 12.96          |
| Religion              |               |                |
| Muslim                | 44            | 10.19          |
| Orthodox              | 382           | 88.43          |
| Protestant            | 6             | 1.39           |
| Occupation            |               |                |
| Employed*             | 228           | 52.78          |
| Unemployed**          | 204           | 47.22          |
| Caregiver             |               |                |
| Family*               | 314           | 72.69          |
| Non-family**          | 76            | 17.59          |
| No caregiver          | 42            | 9.72           |
| Residence             |               |                |
| Within Gondar town (urban) | 353 | 81.71          |
| Out of Gondar town (rural) | 79  | 18.29          |
| Disclosure status     |               |                |
| Disclose              | 196           | 45.37          |
| Not disclose          | 236           | 54.63          |

* Employed—private employee, driver, Governmental employee, Teacher, Merchant, Military
** Unemployed—Housewife, Student, Farmer, unemployed, daily worker
* Family—patient’s husband or wife, child or brother or sister or parents
** Non-family caregiver outside “family” definition

Table 2 Baseline clinical characteristics of adult HIV-positive patients at initiation of ART in Gondar town, October 2016 to April 2021 (n = 432)

| Characteristics                                | Frequency | Percentage (%) |
|------------------------------------------------|-----------|----------------|
| Time of initiation of ART ASM                  |           |                |
| Same day                                       | 269       | 62.3           |
| Not same day                                   | 163       | 37.7           |
| Yes                                            | 357       | 82.6           |
| No                                             | 75        | 17.4           |
| Partner HIV status                             |           |                |
| Positive                                       | 78        | 18.1           |
| Negative                                       | 49        | 11.3           |
| Unknown                                        | 305       | 70.6           |
| TB status at ART initiation                    |           |                |
| Yes                                            | 45        | 10.4           |
| No                                             | 387       | 89.6           |
| Prophylaxis                                    |           |                |
| CPT                                            | 48        | 11.1           |
| INH                                            | 164       | 38.0           |
| Both CPT and INH                               | 69        | 16.0           |
| No prophylaxis                                 | 151       | 35.0           |
| Adherence to ART                               |           |                |
| Good                                           | 317       | 73.4           |
| Fair                                           | 69        | 16.0           |
| Poor                                           | 46        | 10.7           |
| Referral site                                  |           |                |
| Within facility                                | 315       | 72.9           |
| Outside the facility                           | 117       | 27.1           |
| Baseline functional status                     |           |                |
| Working                                        | 366       | 84.7           |
| Ambulatory                                     | 58        | 13.4           |
| Bedridden                                      | 8         | 2.0            |
| Baseline WHO clinical stage                    |           |                |
| I                                              | 310       | 71.7           |
| II                                             | 58        | 13.4           |
| III                                            | 40        | 9.3            |
| IV                                             | 24        | 5.6            |
| Baseline BMI                                   |           |                |
| Under weight                                   | 112       | 25.93          |
| Normal                                         | 268       | 62.04          |
| Overweight or obese                            | 52        | 12.04          |
| Past opportunistic infection                   |           |                |
| Yes                                            | 110       | 25.5           |
| No                                             | 322       | 74.5           |

ASM Appointment spacing model, TB tuberculosis, HIV human immunodeficiency virus, WHO World Health Organization, BMI Body Mass Index, ART antiretroviral therapy
status, on ASM model, being HVL, poor drug adherence, rural residence, and normal BMI were the remaining significant predictors of LTFU (Table 3).

After the multivariable logistic model, a total of six prognostic determinants were left for the prediction of LTFU and the relative contribution of each prognostic determinant to the probability of LTFU was calculated by dividing each beta coefficient by the lowest beta coefficient and rounding to the nearest integer (score chart rule formula) (Table 4).

Therefore, the probability of LTFU among clients on ART using the regression formula was: Linear predictor of the model (lp) = 4.70 + 1.03 * not on prophylaxis + 1.59 * on ASM + 1.12 * Poor adherence status + 1.51 * being HVL + 0.79 * residence (out of Gondar) + 1.01 * normal BMI.

Consequently, the probability of LTFU for each patient was predicted by the regression formula as follows, P(LTFU) = exp(lp) / (1 + exp(lp))

Based on the regression formula, the probability of LTFU for each client on ART was calculated. Thus, using the Youden index value, the cut point for high and low risk for LTFU was determined to be 30.4%. Accordingly, 150 patients were at high risk for LTFU, and among those, 80 (53.3%) clients were lost from care. While 282 (65.3%) clients were at low risk of LTFU, about 31 (11%) were lost. The sensitivity and specificity of the probability of LTFU with the cut point of (30.4%), were 72.07% and 83.5%, respectively. The overall true prediction accuracy of the risk algorithm to predict LTFU was 76.62%, and the false prediction probability was 16.51% (Table 5).

A risk prediction tool has been generated as an excel spreadsheet that can be used in the clinic set up to perform these calculations automatically using information entered about patient’s risk determinants (Additional file 1). To illustrate, consider a patient from a rural setting, who has normal BMI, and is on ASM. Putting this value into the excel spreadsheet gives an estimated probability of LTFU of 17.3% (as shown in Fig. 1a) which is classified as low risk for LTFU. However, if another patient with the same characteristics as the previous patient but with another risk factor of being HVL, adding this information in the tool, gives a revised probability of 48.8% (as shown in Fig. 1b) which turns the patient risk classification from low risk into high risk of LTFU.

Discrimination and calibration ability of the reduced model

The final reduced model discriminative probability was assessed using the AUROC which was 85.9% (95% CI 82.0–89.6) (Fig. 2a). The internal validation of the model was checked through bootstrapping technique by drawing with replacement from the original sample. After 10,000 stratified bootstrap replicates, the AUC was 85.9% with the 95% CI (81.9–89.4%) (Fig. 2c). The model calibration was checked by comparing the agreement between the predicted probability of LTFU against the observed frequency using a calibration plot (p-value=0.350) (Fig. 2b).
Decision curve analysis of the model
Using the model for the prediction of LTFU has a better cost–benefit ratio as shown in Fig. 3. The prognostic model gives highest net benefit. If we take 0.2 risk threshold the net benefit for follow all will be around 0.2. This implies with less risk threshold have less net benefit however that incurs more cost. With the same risk threshold following based on the prognostic model the net benefit will around 0.6, which is low cost.

Table 4 Reduced model prognostic determinants

| Prognostic determinants | AOR (95% CI) | Regression coefficient | Contribution to risk score |
|-------------------------|--------------|------------------------|---------------------------|
| Not on prophylaxis      | 2.82 (1.58–5.03) *** | 1.03                   | 1                         |
| On ASM model            | 4.92 (1.52–15.94) **  | 1.59                   | 2                         |
| Normal BMI              | 2.75 (1.43–5.30) **  | 1.01                   | 1                         |
| Poor adherence status   | 3.07 (1.70–5.57) *** | 1.12                   | 1                         |
| Being HVL               | 4.54 (2.43–8.47) *** | 1.51                   | 2                         |
| Residence (out of Gondar Town) | 2.20 (1.11–4.39) *  | 0.79                   | 1                         |
| Constant                | – 4.70                   |                        |                           |

Significant codes: 0 ‘***’ 0.001 ‘**’ 0.01 ‘*’

ASM Appointment Spacing Model, BMI Body Mass Index, HVL high viral load

Table 5 The prediction of LTFU using the reduced regression formula among HIV clients on ART in Gondar, 2021

| Risk category | Percentage | Number of patients on ART | Incidence of LTFU | SN (%) | SP (%) | PPV (%) | NPV (%) |
|---------------|------------|---------------------------|-------------------|--------|--------|---------|---------|
| Low risk      | < 30.4     | 282 (65.28%)              | 31 (11.0%)        | 72.07  | 83.49  | 60.15   | 89.63   |
| High risk     | ≥ 30.4     | 150 (34.72%)              | 80 (53.33%)       |        |        |         |         |
| Total         | 89.20      | 432 (100%)                | 111 (25.69%)      |        |        |         |         |

SN Sensitivity, SP Specificity, PPV positive predictive value, NPV negative predictive value

Fig. 1 Risk prediction calculator for LTFU among HIV patients on ART in Gondar, as shown in an excel spreadsheet
Clinical prediction and decision rules for LTFU among HIV clients on ART

For the ease of clinical applicability, a score chart rule was developed and with that, the prediction of the risk score tool had eight scores with the AUROC of the simplified risk score 81.0% (95% CI 76.7–85.3%) (Fig. 4). The sensitivity, specificity, positive predictive value, and negative predictive value of each risk score category was also determined (Additional file 2).

For better clinical decision rule, the risk score was categorized as low and high risk of LTFU. The risk score cut point was declared using Youden’s index value, which is the maximum sensitivity and specificity of the risk score. At this risk score value (2.5), the sensitivity and specificity of the risk score AUROC curve were maximized, which is, 64.5% and 85.6%, respectively. Therefore, the individual prediction of LTFU was a high risk if the patient has a risk score value of more than and equal to three (after rounding to the nearest integer).

Based on the risk score category developed, 86 patients had a risk score of less than 3 (low risk). Three hundred forty-six patients had a risk score of more than or equal to 3 (high risk), among them, 110 (31.8%) patients sustained LTFU from care. The sensitivity and specificity of the risk algorithm category were 64.5% and 85.6%, respectively. The positive and negative predictive values of the risk category were 45.45%
and 92.82%, respectively. The overall true prediction accuracy of the risk algorithm to predict LTFU among clients on ART was 82.41%, and the false-positive rate was 17% (Table 6).

Discussion

This is the first prognostic research on LTFU among HIV clients on ART. This study revealed the incidence of LTFU was 11.19 (95% CI 8.95–13.99) per 100-person years. One in 4 patients (25.69%) had LTFU from the treatment in the current study. When compared to findings elsewhere in Ethiopia, the LTFU rate in the present study was higher than findings from Aksum [9], Debre Markos [17], Mizan Teferi [24]. It was similar to results from Gondar [21, 25], South Ethiopia [22], Hadhiya [27] but lower than the findings from Eastern Ethiopia (Jigiga) [11]. In addition, this rate was lower than findings from studies conducted in South Africa [36], Malawi [37], and Guinea-Bissau [38]. The dissimilarity in measurement [39], access to HIV care services, innovation, adoption of new strategies like the universal test and treat approach [40], and difference in year of study could be the possible reasons for variations in rates of LTFU.

In previous years, the focus of the research was to explain the incidence and factors associated with a certain outcome. But in recent years, the emphasis is shifted to predicting the risk using a combined set of characteristics. In our study, a combination of six prognostic determinants (prophylaxis status, ASM status, HVL status, adherence level, residence, BMI status) results in an AUROC of 0.86 (95% CI 0.8–0.9), which is good accuracy according to diagnostic accuracy classification [41, 42]. Having an AUROC of 0.86 (95% CI 0.8–0.9) means that the model is 86% accurate in discriminating between a randomly selected subject who was lost from a randomly selected subject who was not lost from care.

Among the prognostic determinants, HVL status alone has the highest AUC value which is 0.76% (95% CI 0.72–0.81%) followed by prophylaxis and adherence status with an AUC value of 0.71% (95% CI 0.66–0.76%)

Finally, each patient’s risk for LTFU on HAART was predicted using the score chart formula.

\[
\text{Probability of LTFU} = (1 \times \text{not on prophylaxis}) + (2 \times \text{on ASM}) + (1 \times \text{poor adherence}) + (2 \times \text{HVL}) + (1 \times \text{residence, out of Gondar}) + (1 \times \text{Normal BMI}).
\]

**Table 6** Prognostic risk classification of LTFU among HIV clients on ART in Gondar town using simplified prediction risk score among 432 clients

| Risk category | Score range | Prediction of LTFU | Number of HIV patients on ART | Incidence of LTFU | SN (%) | SP (%) | PPV (%) | NPV (%) |
|---------------|-------------|--------------------|-------------------------------|------------------|-------|-------|--------|--------|
| Low risk      | < 3         | 86 (19.91%)        | 1 (1.16%)                     | 85.59            | 64.49 | 45.45 | 92.82  |
| High risk     | ≥ 3         | 346 (80.09%)       | 110 (31.39%)                  |                  |       |       |        |        |
| Total         | 8           | 432 (100%)         | 111 (25.69%)                  |                  |       |       |        |        |

*SN* Sensitivity, *SP* Specificity, *PPV* positive predictive value, *NPV* negative predictive value
and 0.71% (95% CI 0.66–0.76%), respectively. Other’s determinants have low predictive value which is less than 0.70% [ASM status 0.59% (95% CI 0.56–0.62%), normal BMI 0.55% (95% CI 0.56–0.62%), and residence 0.53% (95% CI 0.50–0.60%)].

Though both the regression formula and risk score chart have good accuracy, the AUROC from the regression formula is slightly higher than that of the risk score 0.86 (95% CI 0.8–0.9) vs 0.81 (95% CI 0.77–0.85). Thus, using the regression formula to predict LTFU is better and advisable. The model has also a good calibration with a p-value of 0.350. Good calibration means that the estimated probability of LTFU using the model is similar to the observed LTFU frequency. A statistically significant (p < 0.05) test indicates marked differences between predicted probabilities and observed once and thus poor calibration.

As shown in Fig. 3, the model has the highest net benefit across the entire range of threshold probabilities, which indicates that the model has the highest clinical and public health value. Hence, using the model for the prediction of LTFU has a higher net benefit than not using it. Prognostic research aims to find a risk prediction tool that is simple to use, accurate in predicting risk, generalizable across contexts, and uses routinely collected determinants that are needed to identify patients at high risk for poor outcomes and to provide individualized risk assessment [32]. Thus, clinicians can also use the developed risk score chart for the prediction of LTFU among ART patients as it is simple and has good prediction accuracy (AUC= 81%).

As a result, the overall risk score for the risk prediction tool based on the score chart is 8, and the risk of LTFU grows as the risk score increases. We categorized the cohort into two risk groups in addition to predicting the degree of LTFU risk associated with each risk score. When compared to the low-risk group (risk score less than 3), those in the high-risk category (risk score greater than or equal to 3) had a fourfold (OR 3.68; % CI 1.69–5.66) increased risk of LTFU.

Depending on the availability of resources, health care providers can use different cutoff points. If the providers value sensitivity and specificity equally, the risk score’s cutoff value of 3 maximized the value of both sensitivity and specificity (86% and 64%, respectively). The positive and negative predictive values, respectively, were 45% and 93%. However, health care providers may choose to utilize different cutoff points depending on the importance of false positives and false negatives. A lower risk score cutoff value would target a substantial section of our population for intervention and identify the majority of people who were lost to therapy.

Patients who do not take prophylaxis were found to be at higher risk of LTFU. This was consistent with other studies [21, 24, 25, 27, 28, 31]. This is because of the direct effect of isoniazid in preventing active tuberculosis, which in turn improves the quality of life of patients, which leads to a longer stay in the treatment [21, 25, 27]. The exiting intervention such as management and prevention of opportunistic infections like pneumocystis pneumonia (PCP), toxoplasmosis, bacterial infections and diarrheal diseases through providing prophylaxis like CPT could encourage patients to be engaged and could bring the effort to retain patients from the start of HIV treatment [6, 21, 43].

Patients with suboptimal adherence were at an increased risk of being LTFU when compared with those with exemplary commitment. This was supported by other studies [8, 25, 27]. The possible reason could be patients with suboptimal adherence may have sociodemographic and clinical problems that affect their adherence initially, which further affect retention in care [44]. In addition, patients with suboptimal adherence are at a higher risk of treatment failure, which makes them to be more vulnerable to many opportunistic diseases, with higher chance to have more pill burden, adverse drug toxicities, and interactions among opportunistic infection treatment and ART, which demands a high level of commitment to follow all those medications [44, 45].

This study revealed that rural residents were found to be more likely to be LTFU in the treatment as compared to their counterparts. Studies evidenced that travel time to the clinics and its opportunity costs (in terms of financial cost or time allocated to something else), level of patient’s awareness of the treatment, and social stigma are significant barriers to patient adherence to ART and maintenance in care [18, 37].

Contrary to previous evidences [37, 38, 46], patients who had a normal baseline BMI were about three times more likely to be LTFU in treatment compared to those patients who had low BMI. This may be due to the reason that patients who had a normal baseline BMI may feel that they are well and their health-seeking behavior may be inadequate and patients with low BMI at ART initiation were probably more symptomatic and had counseled about good adherence in the lifelong follow-up treatments, which may have resulted in greater motivation to remain in care [47].

In our study, patients on ASM are at a higher risk of LTFU than patients not on ASM. This may be due to the problem with lower potency of the drug, which may happen due to poor handling of several ART medications that patients have to take for 6 months as well patients
may not disclose their HIV status and thus worried about keeping too many numbers of pills at home without being seen which may have an impact on their adherence [48]. The other reason may be, that patients may not be screened well using the criteria for ASM which patients may have an unseen deadly opportunistic infection like Tuberculosis, a cryptococcal infection that can take the life of such patients. Due to these reasons, patients may be lost from care.

LTFU was also more prevalent in individuals who had HVL in the follow-up. Patients with HVL were almost five times at increased risk of being lost. This is because patients with HIV in the follow-up period are more likely to have problems with adherence, psychosocial issues like fear of stigma, lack of social support, mental illness, substance abuse, poor livening condition, or even primary drug resistance, which have a direct or indirect effect on the continuity of care [43, 49].

This study has some limitations and strengths. Our research is innovative in that it uses routinely collected patient data available in many HIV programs in resource-limited settings, which allows for the model to be used across diverse backgrounds. The model is pragmatic in that it is a simple point-based model that can be calculated by various health care professional’s ranging from providers to adherence counselors. It can be easily adapted to mobile-app technology or the existing electronic medical record (smart care) so that HIV program could use this risk score to identify patients at the highest risk of LTFU after starting treatment and provide such patients with differentiated models of HIV care and interventions to reduce LTFU and the grave consequences following it.

Despite the strengths of this simple risk prediction score model, several limitations need to be acknowledged. First, though the model has good discrimination and calibration in the bootstrapped samples, the model should undergo external validation to see the performance of the risk prediction model/score in other populations. Second, is that we did not include determinants like monthly income, cigarette smoking, alcohol, and substance abuse, hemoglobin level, pain status, Hepatitis B and C status, baseline CD4 count, drug regimen, and adverse drug reactions which could have an impact on LTFU and maybe essential determinants for prediction of LTFU. Thus, the model prediction cannot be extended to such patients, limiting the model’s applicability. Third, the impact of Covid-19 on LTFU among HIV patients on ART was not assessed due to the retrospective nature of the study. Last, our study included people with a new and existing HIV diagnosis. People with a new HIV diagnosis may have different challenges like disclosure, fear of stigma, adherence issues, and modification of life to stay in care. Therefore, they may need a different risk score.

**Conclusion and recommendation**

The incidence of LTFU among clients on ART in Gondar town was high (> 3%), we have identified a set of readily available tools that can be used to predict LTFU among HIV patients on ART. The predictors of LTFU were being HVL, on ASM, not being on prophylaxis, poor drug adherence, rural residence, and normal BMI. The tool has good accuracy and discriminative ability. In addition, the tool can be used to stratify PLHIV into risk groups that can be identified for targeted intervention. In settings with similar demographics, the risk prediction tool can assist clinicians and health care providers to identify high-risk individuals for LTFU and target interventions. Researchers should externally validate the developed prediction model for the applicability of the clinical setup.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12879-022-07691-x.

Additional file 1. Risk prediction calculator for calculation of probability of LTFU among HIV patients on ART in Gondar, Ethiopia.

Additional file 2. Performance of the risk scores at different cutoff points.

**Acknowledgements**

Not applicable.

**Author contributions**

DTF and SAT were involved in this study from the data acquisition, inception to design, data cleaning, data analysis, and interpretation and drafting and revising of the manuscript. AAM and GMK project administration, data analysis and interpretation, drafting and revising the final manuscript. All authors read and approved the final manuscript.

**Funding**

There is no funding for this study.

**Availability of data and materials**

All data analyzed during this study are included in this published article [and its additional information files].

**Declarations**

**Ethics approval and consent to participate**

Ethical clearance was obtained from the institutional review board of the University of Gondar. All methods were carried out in accordance with relevant guidelines following the Declaration of Helsinki. A waiver of informed consent was obtained from the institutional review board of the University of Gondar.

A permission letter was also obtained from the Gondar health department and institutional review board of the University of Gondar. A waiver of informed consent was also obtained from each health institute head and HIV care clinic focal person to use the secondary data for this study.

The name or any other identifying information was not recorded on the questionnaire, and all the information taken from the chart was kept strictly confidential and in a locked cabinet.
References

1. WHO. HIV/AIDS key facts 2020. https://www.who.int/news-room/fact-sheets/detail/hiv-aids.
2. Wandelger G, Johnson LF, Egger M. Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population. Curr Opin HIV AIDS. 2016;11(5):492–500.
3. Fox MP, Rosen S. Retention of adult patients on antiretroviral therapy in low- and middle-income countries: systematic review and meta-analysis 2008–2013. J Acquir Immune Defic Syndr. 2015;69(1):98–108.
4. UNAIDS. Fast track ending the AIDS epidemic by 2030.
5. Arstenn JH, Dernas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang C-J, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33(8):1417–23.
6. Frijters EM, Hermans LE, Wensing AMJ, Deville W, Tempelman HA, De Wit JBF. Risk factors for loss to follow-up from antiretroviral therapy programmes in low-income and middle-income countries. AIDS. 2020;34(9):1261–88.
7. WHO. Ethiopia HIV country profile. 2016. 2017; WHO/HIV/2017.59.
8. Abebe Moges N, Olubukola A, Micheal O, Berhane Y. HIV patients retention and attrition in care and their determinants in Ethiopia: a systematic review and meta-analysis. BMC Infect Dis. 2020;20(1):439.
9. Tadesse K, Fisaha H. Predictors of loss to follow-up of patients enrolled on antiretroviral therapy: a retrospective cohort study. J AIDS Clin Res. 2014;5:12.
10. Bucciardini R, Tatarelli P, Hermands LE, Wensing AMJ, Deville W, Tempelman HA, De Wit JBF. Risk factors for loss to follow-up from antiretroviral therapy programmes in low-income and middle-income countries. AIDS. 2020;34(9):1261–88.
11. WHO. Ethiopia HIV country profile. 2016. 2017; WHO/HIV/2017.59.
12. Bucciardini R, Tatarelli P, Hilawe EH, Fragola V, Abegaz T, Lucattini S, Halifom A, Tadesse E, Di Gregorio M, Katherina, Pugliese RT, Vella S, Godsey H. Gender differences in death and loss to follow-up among HIV-positive patients on Antiretroviral Therapy in Tigray, Ethiopia. Ethiop Med J. 2019;57(2):227–33.
13. Seifu W, Ali W, Meresa B. Predictors of loss to follow up among adult clients attending antiretroviral treatment at Karamara general hospital, Jigjiga town, Eastern Ethiopia, 2015: a retrospective cohort study. BMC Infect Dis. 2018;19(1):280.
14. Berheto TM, Hinderaker SG, Senkoro M, Tweya H, Deressa T, Getaneh Y, et al. Body and mind: retention in antiretroviral treatment care is improved by mental health training of care providers in Ethiopia. BMC Public Health. 2018;18(1):896.
15. Gesesse HA, Ward P, Molde Michael K, Mwanri L. Prevalence, trend and risk factors for antiretroviral therapy discontinuation among HIV-infected adults in Ethiopia in 2003–2015. PLoS ONE. 2017;12(6):e0179533.
16. Bucciardini R, Fragola V, Abegaz T, Lucattini S, Halifom A, Tadesse E, et al. Predictors of attrition from care at 2 years in a prospective cohort of HIV-infected adults in Tigray, Ethiopia. BMJ Glob Health. 2017;2(3):e000325.
17. Melaku Z, Lamb MR, Wang C, Lulseged S, Gadisa T, Ahmed S, et al. Characteristics and outcomes of adult Ethiopian patients enrolled in HIV care and treatment: a multi-clinic observational study. BMC Public Health. 2015;15:462.
18. Bucciardini R, Fragola V, Abegaz T, Lucattini S, Halifom A, Tadesse E, et al. Retention in care of adult HIV patients initiating antiretroviral therapy in Tigray, Ethiopia: a prospective observational cohort study. PLoS ONE. 2015;10(9):e0156117.
19. Birhanu MY, Leshargie CT, Abebel A, Wagnew F, Siferih M, Gebre T, et al. Incidence and predictors of loss to follow-up among HIV-positive adults in northwest Ethiopia: a retrospective cohort study. Trop Med Health. 2020;48:78.
20. Megenso A, Garoma S, Eticha T, Workineh T, Daba S, Tarekegn M, et al. Predictors of loss to follow-up in antiretroviral treatment for adult patients in the Oromia region. Ethiopia. HIV/AIDS. 2016;8:83–92.
21. Tesfaye Asefa MT, Dejene T, Duble L. Determinants of defaulting from antiretroviral therapy treatment in Nekemte Hospital, Eastern Wollega Zone, Western Ethiopia. Public Health Res. 2013.
22. Derbe T, Hailekeros F, Bladiglign S, Amberbir A, Beyene BK. defaulters from antiretroviral treatment in Jimma University Specialized Hospital, Southwest Ethiopia. Trop Med Int Health. 2008;13(3):328–33.
23. Teshale AB, Tsegaye AT, Wolde H. Incidence and predictors of loss to follow-up among adult HIV patients on antiretroviral therapy in University of Gondar Comprehensive Specialized Hospital: a competing risk regression modeling. PLoS ONE. 2020;15(1):e0227473.
24. Teshome W, Belayneh M, Moges M, Melknennen E, Endrias M, Ayele S, et al. Do loss to follow-up and death rates from ART care vary across primary health care facilities and hospitals in south Ethiopia? A retrospective follow-up study. HIV/AIDS. 2015;7:167–74.
25. Tadege M. Predictors associated with HIV/AIDS patients dropout from antiretroviral therapy at Mettu Karl Hospital, southwest Ethiopia. BMC Res Notes. 2019;12(1):232.
26. Berheto TM, Haile DB, Mohammed S. Predictors of loss to follow-up in patients living with HIV/AIDS after initiation of antiretroviral therapy. N Am J Med Sci. 2014;6(9):453–9.
27. Melknennen N, Abdulkadir M, Shumetie E, Baraki AG, Yenit MK. Incidence and predictors of loss to follow-up among HIV infected adults after initiation of first line anti-retro viral therapy at University of Gondar comprehensive specialized Hospital Northwest Ethiopia, 2018: retrospective follow up study. BMC Res Notes. 2019;12(1):111.
28. Telele NF, Kalu AW, Mamone G, Gebese Selassie S, Fekade D, Tegbaru B, et al. Baseline predictors of antiretroviral treatment failure and loss to follow up in a multicenter countrywide HIV-1 cohort study in Ethiopia. PLoS ONE. 2018;13(7):e0200505.
29. Mensheh T, Birhanu S, Gebremaryam T, Yismaw W, Endalamaw A. Incidence and predictors of Loss to Follow-Up Among Children Attending ART Clinics in Northeast Ethiopia: A Retrospective Cohort Study. HIV AIDS (Auckl). 2021;13:801–12.
30. Assemie MA, Muchie KF, Ayele TA. Incidence and predictors of loss to follow up among HIV-infected adults at Pawi General Hospital, northwest Ethiopia: competing risk regression model. BMC Res Notes. 2018;11(1):287.
31. Gezae KE, Abebe HT, Gebretsadik LG. Incidence and predictors of LTFU among adults with TB/HIV co-infection in two governmental hospitals, Mekelle, Ethiopia, 2009–2016: survival model approach. BMC Infect Dis. 2019;19(1):107.
32. Abira Gesesev H, Asefa H, Shaweno AT. Time to attrition and factors associated among adults enrolled in Pre-Anti-Retroviral Therapy Care in Tepa General Hospital, Ethiopia. Int J Health Med. 2018;3(2).
33. Mehari D, Mache T, Hailemariam L. Predictors of lost to follow up to antiretroviral therapy in primary public hospital of Wukro, Tigray, Ethiopia: a case control study. J AIDS HIV Res. 2015;7(1):1–9.
34. McNairy ML, Abrams EJ, Rabkin M, El-Sadr WM. Clinical decision tools are needed to identify HIV-positive patients at high risk for poor outcomes after initiation of antiretroviral therapy. PLoS Med. 2017;14(4):e1002278.
35. McNairy ML, Jamnati-Khal D, Pape JW, Marcelin A, Joseph P, Mathon JE, et al. Predicting death and lost to follow-up among adult patients initiating antiretroviral therapy in resource-limited settings: derivation and external validation of a risk score in Haiti. PLoS ONE. 2018;13(8):e0201945.
36. Ryley RD, Ensor J, Snell KE, Harrell FE Jr, Martin GP, Reitsma JB, et al. Calculating the sample size required for developing a clinical prediction model. BMJ. 2020;368:m441.
37. Gebremariam AD, Tinuneh SA, Engdaw MT, Tesfa D, Azanaw MM, Yitbarek GY, et al. Development and validation of a clinical prognostic risk score to predict early neonatal mortality, Ethiopia: a receiver operating characteristic curve analysis. Clin Epidemiol. 2021;13:637.
38. Mberi MN, Kuonzia LR, Duble NW, Nattey C, Manda S, Summers R. Determinants of loss to follow-up in patients on antiretroviral treatment. South Africa, 2004–2012: a cohort study. BMC Health Serv Res. 2015;15:259.
37. Tweya H, Oboho IK, Gugsa ST, Phiri S, Rambiki E, Banda R, et al. Loss to follow-up before and after initiation of antiretroviral therapy in HIV facilities in Lilongwe, Malawi. PLoS ONE. 2018;13(1):e0188488.

38. Honge BL, Jespersen S, Nordenfelt PB, Medina C, da Silva D, da Silva ZJ, et al. Loss to follow-up occurs at all stages in the diagnostic and follow-up period among HIV-infected patients in Guinea-Bissau: a 7-year retrospective cohort study. BMJ Open. 2013;3(10):e003499.

39. Chalker JM, Andualem T, Minzi O, Ntaganira J, Ojoo A, Waako P, Ross-Degnan D. Monitoring adherence and defaulting for antiretroviral therapy in 5 East African Countries: an urgent need for standards. J Int Assoc Physicians AIDS Care. 2008;7:4.

40. Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. JAMA. 2009;301(22):2380–2.

41. Swets AJ. Measuring the accuracy of diagnostic systems. Science. 1988;240(4857):1285–93.

42. Kumar R, Indrayan A. Receiver operating characteristic (ROC) curve for medical researchers. Indian Pediatr. 2011;48(4):277–87.

43. Health BMo. National comprehensive HIV care Guideline 2018.pdf. 2018, August.

44. Fonsah JY, Njamnshi AK, Kouanfack C, Qiu F, Njamnshi DM, Tagny CT, et al. Adherence to Antiretroviral Therapy (ART) in Yaounde-Cameroun: association with opportunistic infections, depression, ART regimen and side effects. PLoS ONE. 2017;12(1):e0170893.

45. Saka B, Landoh DE, Patassi A, d’Almeida S, Singo A, Gessner BD, et al. Loss of HIV-infected patients on potent antiretroviral therapy programs in Togo: risk factors and the fate of these patients. Pan Afr Med J. 2013;15:35.

46. Dessu S, Mesele M, Habte A, Dawit Z. Time until loss to follow-up, incidence, and predictors among adults taking ART at Public Hospitals in Southern Ethiopia. HIV/AIDS. 2021;13:205–15.

47. Mancinelli S, Nielsen-Saines K, Germano P, Guidotti G, Buonomo E, Scarcella P, et al. Who will be lost? Identifying patients at risk of loss to follow-up in Malawi. The DREAM Program Experience. HIV Med. 2017;18(8):573–9.

48. Sida F. Experiences of health care workers and patients on appointment spacing model: The case of Bishoftu Hospital and Bishoftu Health Center. ACIPH. 2019.

49. Dejen D, Jara D, Yeshanew F, Fentaw Z, Mengie Feleke T, Girmaw F, et al. Attrition and its predictors among adults receiving first-line antiretroviral therapy in Woldia Town Public Health Facilities, Northeast Ethiopia: a retrospective cohort study. HIV/AIDS. 2021;13:445–54.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.